Literature DB >> 34762228

Association of immunological features with clinical manifestations in primary Sjogren's syndrome: a single-center cross-sectional study.

Hitesh Srinivasa Krishna Relangi1, G S R S N K Naidu2, Vikas Sharma3, Mahendra Kumar4, Varun Dhir1, Shefali K Sharma1, Aman Sharma1, Ranjana W Minz4, Sanjay Jain1.   

Abstract

The objectives of this study were to describe the clinical features and evaluate the utility of immunological features as predictors of organ involvement and disease severity in patients with primary Sjogren's syndrome (pSS). In this single-center observational cross-sectional study, subjects fulfilling the 2012 AECG criteria or 2016 ACR/EULAR criteria for pSS were included. Details of glandular, extra-glandular manifestations, ESSDAI, ESSPRI, ANA, anti-Ro/La antibodies, rheumatoid factor (RF), complement (C3 and C4) levels and hyperglobulinemia were noted. Chi-square and Mann-Whitney U tests were performed for determining associations and relative risk (RR) was calculated. Sixty-four subjects with pSS were included in the study. Females constituted 92% and median age at onset was 37.5 (15-74) years. Ocular or oral sicca was noted in 61 (95.3%) subjects and parotidomegaly was noted in 17 (26.5%) subjects. Extra-glandular manifestations noted were: constitutional (85.9%), articular (65.6%), renal (29.6%), hematological (26.6%), cutaneous (12.5%), peripheral nerves (9.3%) and pulmonary (4.7%). Immunological features noted were: ANA (85.9%), anti-Ro (81.3%), anti-La (60.9%), RF (84.4%), hypocomplementemia (39.1%) and hyperglobulinemia (62.5%). Median ESSDAI was 6 (0-23) and ESSPRI was 7 (0-10). ANA was associated with younger age and renal involvement (RR 1.25). Anti-Ro was associated with younger age, renal involvement (RR 1.36) and high ESSDAI. Anti-La was associated with high renal (RR 3.4) and low articular involvement (RR 2.75). RF was associated with hematological involvement and hyperglobulinemia was associated with younger age. Certain immunological features can help predict the organ involvement in patients with pSS. Larger, prospective follow-up studies are needed to clearly understand these associations.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoantibodies; Complements; ESSDAI; Hyperglobulinemia; Primary Sjogren’s syndrome

Year:  2021        PMID: 34762228     DOI: 10.1007/s10238-021-00772-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  3 in total

Review 1.  Sjogren's syndrome--diagnosis and management.

Authors:  K M Mahendranath
Journal:  J Assoc Physicians India       Date:  2006-06

2.  Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome.

Authors:  Soledad Retamozo; Miriam Akasbi; Pilar Brito-Zerón; Xavier Bosch; Albert Bove; Marta Perez-de-Lis; Iratxe Jimenez; Maria-Jose Soto-Cardenas; Miriam Gandia; Candido Diaz-Lagares; Odette Viñas; Antoni Siso; Roberto Perez-Alvarez; Jordi Yague; Manuel Ramos-Casals
Journal:  Clin Exp Rheumatol       Date:  2012-10-17       Impact factor: 4.473

3.  How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project).

Authors:  Pilar Brito-Zerón; Nihan Acar-Denizli; Wan-Fai Ng; Margit Zeher; Astrid Rasmussen; Thomas Mandl; Raphaele Seror; Xiaomei Li; Chiara Baldini; Jacques-Eric Gottenberg; Debashish Danda; Luca Quartuccio; Roberta Priori; Gabriela Hernandez-Molina; Berkan Armagan; Aike A Kruize; Seung-Ki Kwok; Marika Kvarnström; Sonja Praprotnik; Damien Sène; Elena Bartoloni; Roser Solans; Maureen Rischmueller; Yasunori Suzuki; David A Isenberg; Valeria Valim; Piotr Wiland; Gunnel Nordmark; Guadalupe Fraile; Hendrika Bootsma; Takashi Nakamura; Roberto Giacomelli; Valerie Devauchelle-Pensec; Andreas Knopf; Michele Bombardieri; Virginia-Fernandes Trevisani; Daniel Hammenfors; Sandra G Pasoto; Soledad Retamozo; Tamer A Gheita; Fabiola Atzeni; Jacques Morel; Cristina Vollenveider; Ildiko-Fanny Horvath; Kathy L Sivils; Peter Olsson; Salvatore De Vita; Jorge Sánchez-Guerrero; Levent Kilic; Marie Wahren-Herlenius; Xavier Mariette; Manuel Ramos-Casals
Journal:  Clin Exp Rheumatol       Date:  2018-08-14       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.